Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan

被引：31
作者：
Carroll, Robert P. [1 ,2 ,3 ,4 ]
Riceman, Michael [1 ,2 ]
Hope, Christopher M. [1 ,2 ]
Zeng, Anna [1 ,2 ]
Deayton, Sue [3 ]
Bennett, Greg D. [3 ]
Coates, P. T. [1 ,2 ,3 ]
机构：
[1] CNARTS, Adelaide, SA, Australia
[2] Univ Adelaide, Dept Med, Adelaide, SA, Australia
[3] Australian Red Cross Blood Serv, Adelaide, SA, Australia
[4] Univ South Australia, Adelaide, SA, Australia
来源：
HUMAN IMMUNOLOGY | 2016年 / 77卷 / 12期
关键词：
Antibodies; Biomarker; Rejection; Renal; Transplantation; ACTIVATING ANTIBODIES; MEDIATED REJECTION; TRANSPLANTATION; RISK;
D O I：
10.1016/j.humimm.2016.08.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Angiotensin II type 1 antibodies (AT1Rab) can mediate antibody mediated rejection (AMR). Pre transplant AT1Rab levels, and risk of rejection were assessed in Kidney Transplant Recipients (KTR) transplanted in our centre from 2013 to 2014 (n = 145). 14/145 (9.7%) KTR experienced antibody mediated rejection (AMR). The Hazard Ratio for AMR = 3.7 [95% CI 2-26] (p = 0.009) for KTR with AT1Rab levels >17.5 U/ml. 6/11 of KTR with levels >25 U/ml experienced AMR. In 2015 (n = 80) KTR were transplanted and 6/80 KTR experienced rejection (2 AMR and 4 TCMR with vascular lesions). 7/80 of KTR had AT1Rab 17.5-25 U/ml and none experienced rejection and were induced with ATG and candesartan. 7/80 had AT1Rab 25-40 U/ml and received pre and post-operative plasma exchange, ATG and candesartan and 1/7 experienced TCMR with a vascular lesion. This perioperative regimen may alter the risk of rejection in patients with high levels of AT1Ab and further studies are needed. (C) 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：1154 / 1158
页数：5
相关论文
共 11 条
[1]   The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes [J].
Banasik, Miroslaw ;
Boratynska, Maria ;
Koscielska-Kasprzak, Katarzyna ;
Kaminska, Dorota ;
Bartoszek, Dorota ;
Zabinska, Marcelina ;
Myszka, Marta ;
Zmonarski, Slawomir ;
Protasiewicz, Marcin ;
Nowakowska, Beata ;
Halon, Agnieszka ;
Chudoba, Pawel ;
Klinger, Marian .
TRANSPLANT INTERNATIONAL, 2014, 27 (10) :1029-1038
[2]   Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection [J].
Dragun, D ;
Müller, DN ;
Bräsen, JH ;
Fritsche, L ;
Nieminen-Kelhä, M ;
Dechend, R ;
Kintscher, U ;
Rudolph, B ;
Hoebeke, J ;
Eckert, D ;
Mazak, I ;
Plehm, R ;
Schönemann, C ;
Unger, T ;
Budde, K ;
Neumayer, HH ;
Luft, FC ;
Wallukat, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :558-569
[3]   Kidney Allograft Survival After Acute Rejection, the Value of Follow-Up Biopsies [J].
El Ters, M. ;
Grande, J. P. ;
Keddis, M. T. ;
Rodrigo, E. ;
Chopra, B. ;
Dean, P. G. ;
Stegall, M. D. ;
Cosio, F. G. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (09) :2334-2341
[4]   Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death [J].
Fidler, Samantha J. ;
Irish, Ashley B. ;
Lim, Wai ;
Ferrari, Paolo ;
Witt, Campbell S. ;
Christiansen, Frank T. .
TRANSPLANT IMMUNOLOGY, 2013, 28 (04) :148-153
[5]  
Fuss A., 2015, NEPHROLOGY
[6]   Pretransplant Sensitization Against Angiotensin II Type 1 Receptor Is a Risk Factor for Acute Rejection and Graft Loss [J].
Giral, M. ;
Foucher, Y. ;
Dufay, A. ;
Van Huyen, J. P. D. ;
Renaudin, K. ;
Moreau, A. ;
Philippe, A. ;
Hegner, B. ;
Dechend, R. ;
Heidecke, H. ;
Brouard, S. ;
Cesbron, A. ;
Castagnet, S. ;
Devys, A. ;
Soulillou, J. P. ;
Dragun, D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (10) :2567-2576
[7]   Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions [J].
Haas, M. ;
Sis, B. ;
Racusen, L. C. ;
Solez, K. ;
Glotz, D. ;
Colvin, R. B. ;
Castro, M. C. R. ;
David, D. S. R. ;
David-Neto, E. ;
Bagnasco, S. M. ;
Cendales, L. C. ;
Cornell, L. D. ;
Demetris, A. J. ;
Drachenberg, C. B. ;
Farver, C. F. ;
Farris, A. B., III ;
Gibson, I. W. ;
Kraus, E. ;
Liapis, H. ;
Loupy, A. ;
Nickeleit, V. ;
Randhawa, P. ;
Rodriguez, E. R. ;
Rush, D. ;
Smith, R. N. ;
Tan, C. D. ;
Wallace, W. D. ;
Mengel, M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (02) :272-283
[8]   Antibody-mediated vascular rejection of kidney allografts: a population-based study [J].
Lefaucheur, Carmen ;
Loupy, Alexandre ;
Vernerey, Dewi ;
Duong-Van-Huyen, Jean-Paul ;
Suberbielle, Caroline ;
Anglicheau, Dany ;
Verine, Jerome ;
Beuscart, Thibaut ;
Nochy, Dominique ;
Bruneval, Patrick ;
Charron, Dominique ;
Delahousse, Michel ;
Empana, Jean-Philippe ;
Hill, Gary S. ;
Glotz, Denis ;
Legendre, Christophe ;
Jouven, Xavier .
LANCET, 2013, 381 (9863) :313-319
[9]   Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies [J].
Opelz, G .
LANCET, 2005, 365 (9470) :1570-1576
[10]   Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation [J].
Reinsmoen, Nancy L. .
HUMAN IMMUNOLOGY, 2013, 74 (11) :1474-1477
12